Literature DB >> 11839442

Intestinal absorption characteristics of the low solubility thiocarboxanilide UC-781.

S Deferme1, J Van Gelder, F Ingels, G Van den Mooter, S De Buck, J Balzarini, L Naesens, E De Clercq, R Kinget, P Augustijns.   

Abstract

The aim of this study was to determine the intestinal absorption characteristics of the antiviral agent UC-781 and to optimize the experimental conditions of the in vitro system for low solubility compounds. The absorption potential of UC-781 was studied with the Caco-2 system and with the rat intestinal perfusion technique. The low solubility of UC-781 required the use of solubility/dissolution rate enhancing agents (e.g. VitE-TPGS, Gelucire 44/14). The creation of sink conditions in the receiver compartment of the Caco-2 system was a prerequisite to reliably study the transport of this poorly soluble compound. After inclusion of VitE-TPGS in the acceptor solution, UC-781 could be characterized as a class II drug of the Biopharmaceutical Classification System (low solubility, high permeation across membranes). A significant concentration-dependent decrease in transport of UC-781 was observed upon increasing the concentration of VitE-TPGS in the apical compartment. This observation contrasts to the absorption enhancing properties of VitE-TPGS, and can probably be attributed to a decrease in the concentration of free UC-781 when using higher concentrations of the solubility/dissolution rate enhancing agents. The use of Gelucire 44/14 as a solubilizing agent resulted in a batch-dependent degradation of UC-781. The inclusion of the solubility/dissolution rate-enhancing agent VitE-TPGS did not result in absorption enhancement in the intestinal perfusion technique.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839442     DOI: 10.1016/s0378-5173(01)00952-8

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  3 in total

1.  Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781.

Authors:  Haitao Yang; Michael A Parniak; Charles E Isaacs; Sharon L Hillier; Lisa C Rohan
Journal:  AAPS J       Date:  2008-12-17       Impact factor: 4.009

2.  Solid Lipid Nanoparticles as Formulative Strategy to Increase Oral Permeation of a Molecule Active in Multidrug-Resistant Tuberculosis Management.

Authors:  Antonella Obinu; Elena Piera Porcu; Sandra Piras; Roberta Ibba; Antonio Carta; Paola Molicotti; Rossana Migheli; Alessandro Dalpiaz; Luca Ferraro; Giovanna Rassu; Elisabetta Gavini; Paolo Giunchedi
Journal:  Pharmaceutics       Date:  2020-11-24       Impact factor: 6.321

3.  Influence of Ethanol as a Co-Solvent in Cyclodextrin Inclusion Complexation: A Molecular Dynamics Study.

Authors:  Kanokthip Boonyarattanakalin; Helmut Viernstein; Peter Wolschann; Luckhana Lawtrakul
Journal:  Sci Pharm       Date:  2015-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.